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Objective. As recent participants in an integrated prostate cancer (PCa) care center, we sought to evaluate whether ﬁnancial
investment in an intensity-modulated radiation therapy (IMRT) center resulted in an increased utilization of radiation therapy
in our patients with newly diagnosed PCa. Materials & Methods. Following institutional review board approval, we retrospectively
reviewed the records of all consecutive patients who were diagnosed with prostate cancer in the 12 months prior to and after
investment in IMRT. Primary treatment modalities included active surveillance (AS), brachytherapy (BT), radiation therapy
(XRT), radical prostatectomy (RP), and androgen deprivation therapy (ADT). Treatment data were available for all patients
and were compared between the two groups. Results. A total of 344 patients with newly diagnosed PCa were evaluated over
the designated time period. The pre-investment group totaled 198 patients, while 146 patients constituted the post-investment
group. Among all patients evaluated, there was a similar rate in the use of XRT (20.71% versus 20.55%, P = 1.000) pre- and
post-investment in IMRT. Conclusions. Financial interest in IMRT by urologists does not impact overall utilization rates among
patients with newly diagnosed PCa at our center.
1.Introduction
Prostate cancer (PCa) is the most common solid organ
malignancyinAmericanmenwithglobalstatisticsmirroring
those found in the United States [1]. Screening with prostate
speciﬁc antigen (PSA) has resulted in a signiﬁcant stage mi-
gration such that the majority of new cases of PCa are now
detectedwhilethediseaseisstillclinicallylocalized[2].These
patients canchoose fromseveraltreatmentoptions andmust
weigh the potential morbidity of each treatment modality on
their quality of life. In the vast majority of cases, urologists
are the primary physicians that diagnose these patients with
PCa and are typically involved in the initial work up, dis-
cussion of all treatment options, and counseling of patients.
Urologists are not only intimately involved with the treat-
ment of the primary disease but also the consequential
treatment-related complications while overseeing the long-
term followup of these patients.
Severalcentershavebeenrecentlyestablishedwhereurol-
ogists partner with radiation oncologists acquire ownership
interest in intensity-modulated radiation therapy (IMRT)
equipment and provide integrated prostate cancer care.
Although not yet validated in the literature, this may allow
for improved quality of care and decreased cost. Unfor-
tunately, these eﬀorts have been much maligned in both
the media and radiation oncology literature as conduits to
increased revenue for the urologists with only debatable pa-
tientbeneﬁt[3,4].Thesereportshavenotyetbeensupported
by data.
After acquiring ﬁnancial interest in an integrated pros-
tate cancer center, we sought to evaluate whether our in-
vestment in IMRT resulted in an increased utilization of2 ISRN Urology
radiation therapy in our patients with newly diagnosed pros-
tate cancer.
2.MaterialsandMethods
In September of 2008, we acquired ﬁnancial interest in
an integrated PCa center oﬀering IMRT. Following institu-
tional board approval, we identiﬁed all patients who were
diagnosed with PCa in the 12 months before and after
the center became operational. Newly diagnosed cases of
PCa were identiﬁed by searching our electronic medical
record using both prostate biopsy CPT codes (transrectal
ultrasound-guided [TRUS] needle biopsy of the prostate,
55700/76942/76872) and the ICD-9 prostate cancer diagnos-
tic code (prostate cancer, 185.0). All men were diagnosed
with PCa after pathologic review of biopsy needle cores
obtained after TRUS. Indications for biopsy included ele-
vated PSA, abnormal digital rectal exam, abnormal PCA 3
test, and/or strong family history of PCa. Prostate biopsies
were performed utilizing a routine sextant pattern with at
least 12 cores obtained. In cases where clinically indicated,
an extended template biopsy with a higher number of cores
obtained was utilized. The medical records of these patients
were retrospectively reviewed and the data pertaining to the
patients’ demographics, cancer parameters, and initial PCa
treatment modality were extracted.
Patients were assigned to two discrete groups based on
the date of their PCa diagnosis as it related to the date of the
ﬁrstavailabilityofIMRTatourintegratedprostatecenter.All
consecutive patients diagnosed with PCa on a biopsy within
12 months prior to availability of IMRT constituted the
pre-investment group and all consecutive patients diagnosed
with prostate cancer on a biopsy in the 12 months following
initiation of IMRT services constituted the post-investment
group. No patient, regardless of comorbidity, was excluded
from the analysis. The primary treatments received were
designated as active surveillance (AS), brachytherapy (BT),
radiation therapy (XRT), radical prostatectomy (RP), and
androgen deprivation therapy (ADT). Treatment data were
available for all patients and were stratiﬁed by the patient’s
age and Gleason score. The age of 70 years old served as
a cut-oﬀ point as in our clinical practice most of these
patients are deemed suboptimal surgical candidates because
of increased risk of postoperative urinary incontinence and
erectile dysfunction.
Our integrated PCa center was established in collab-
oration with an academic radiation oncology department
from a National Cancer Institute (NCI) designated cancer
centerwithanationwidereputationforclinicalandacademic
excellence. The radiation oncologists that treat our patients
are not employed by the cancer center, but serve as full
time academic faculty and have no ﬁnancial interest in
IMRT. Radiation oncology residents have the opportunity to
participate in all aspects of planning and delivery of radia-
tion therapy. The center also employs a nurse-practitioner
chargedexclusivelywiththecoordinationandsupportofon-
going clinical research programs.
Patients who were referred to us for second opinion with
biopsy-proven PCa as well as men referred to us speciﬁcally
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Figure 1: Gleason score distribution.
for robotic-assisted laparoscopic radical prostatectomy were
excluded to eliminate the potential biases resulting from
the treatment recommendations rendered by an outside
urologist. The overwhelming majority of these patients
choose surgical therapy and their inclusion would skew
the results toward lower utilization rates of XRT. Statistical
analysis was performed using GraphPad InStat version 3.0,
La Jolla, CA. Unpaired t-tests, Chi-squared tests, and Fisher’s
exact tests were implemented as appropriate. P value < 0.05
was considered to represent statistical signiﬁcance.
3. Results
A total of 344 patients were diagnosed with PCa on TRUS
biopsy over the designated 24-month time period. Of the
total patient population, 198 men were diagnosed with PCa
in the 12 months preceding availability of IMRT, while 146
men constituted the post-investment group. Patient and
cancer characteristics were similar between the two groups
(Table 1 and Figure 1). The percentage of patients with
Gleason 7PCa was higher in the post-investment group but
did not reach statistical signiﬁcance, P = 0.073 (Figure 1).
Overall, the use of radiation therapy for those patients
with newly diagnosed PCa following investment in IMRT
(20.55% versus 20.71%, P = 1.00) was similar between the
two patient populations (Table 2 and Figure 2). The number
of patients treated with RP (67.81% versus 71.72%, P =
0.729), AS (9.59% versus 4.55%, P = 0.177), ADT (1.37%
versus 2.02%, P = 0.999), and BT (0.68% versus 1.01%,
P = 0.999) werenot signiﬁcantlydiﬀerentbetweenpost- and
pre-investment groups.
While overall treatment trends aﬀord succinct analysis,
clinicaldecisionsregardingtreatmentofPCaareoftendriven
by a multitude of patient-speciﬁc factors. As such, the data
was analyzed stratifying both Gleason score and age (70
years old serving as a cutoﬀ point). Treatments stratiﬁed
by patient age are shown in Table 3 and Figure 3. Despite
the increased incidence of Gleason score ≥7 disease in the
post-investment group, there was no signiﬁcant diﬀerence
between the groups in all treatment patterns in men less than
70 years of age (Table 3). An increase was found in the use ofISRN Urology 3
Table 1: Patient Characteristics.
Pre-investment % Pre-investment Post-investment % Post-investment P value
Age (years) 67.5 66.1 0.174
PSA (ng/mL) 5.56 6.54 0.291
Gls 6 128 64.65 82 56.16 0.073
Gls 7 54 27.27 54 36.99 0.073
Gls 8+ 16 8.08 10 6.85 0.293
Table 2: Overall Treatment Distribution.
Pre-investment % Pre-investment Post-investment % Post-investment P value
AS 9 4.55 14 9.59 0.177
BT 2 1.01 1 0.68 0.999
XRT 41 20.71 30 20.55 1.000
RP 142 71.72 99 67.81 0.729
ADT 4 2.02 2 1.37 0.999
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Figure 2: Overall treatment distribution.
XRT in men older than 70 years of age in the pre-investment
group(45.45%)ascomparedtomenfollowingacquisitionof
IMRT (55.32%), but this did not reach statistical signiﬁcance
(P = 0.355).
Analyzed by age and Gleason score simultaneously, there
was no diﬀerence between the treatment groups in patients
younger than 70 regardless of the Gleason score, Table 4(a)
and Figure 4(a). For men 70 years or older with Gleason
6 disease, there was a trend toward increased use of AS
(34.78% versus 15.79%) and decreased use of RP (21.74%
versus 31.58%), but did not reach statistical signiﬁcance
(Table 4(b)). There was no diﬀerence (43.48% versus
42.11%) in the use of XRT for men over 70 with Gleason
6 disease. For patients with Gleason 7 disease, there was
a statistically signiﬁcant increase in the utilization of XRT
(pre-investment41.38%versuspost-investment68.42%,P =
0.035) and decrease in the use of RP in the post-investment
group (15.79% versus 55.17%, P = 0.006) seen in Table 4(b)
and Figure 4(b). There was no diﬀerence between treatment
groups in men over 70 with Gleason 8 disease.
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Figure 3: Treatment choice stratiﬁed by patient age.
4. Discussion
External beam radiation therapy is widely used and is an
eﬀective treatment option for localized PCa. There is now
Level I evidence that high-dose radiation therapy decreases
theriskofbiochemicalfailureinmenwithclinicallylocalized
prostate cancer as compared to conventional dose conformal
radiation [5–7]. This improvement, however, comes at a cost
of increased gastrointestinal (GI) and genitourinary (GU)
toxicity. Zietman et al. observed that 2% of men receiving
high-dose radiation experienced acute urinary or rectal
morbidity of radiation therapy oncology group (RTOG)
grade 3 or greater [7]. Furthermore, about 3% of patients
experienced late RTOG grade 3 morbidity.
Intensity modulated radiation therapy allows for delivery
of radiation with greater conformality to the target volume
compared with traditional 3 D technique. Several random-
ized trials have shown that IMRT reduced GI and GU
toxicity compared with 3 D conformal radiation [8–10].
Zelefsky et al. were able to deliver 81Gy with less than 2%4 ISRN Urology
Table 3: Treatment Choice Stratiﬁed by Age.
Pre-investment Post-investment
<70yrs % >70yrs % <70yrs % >70yrs %
Gls 6 90 74.38 38 49.35 59 59.60 23 48.94
Gls 7 25 20.66 29 37.66 35 35.35 19 40.43
Gls 8+ 6 4.96 10 12.99 5 5.05 5 10.64
AS 3 2.48 6 7.79 5 5.05 9 19.15
BT 0 0.00 2 2.60 1 1.01 0 0.00
XRT 6 4.96 35 45.45 4 4.04 26 55.32
RP 112 92.56 30 38.96 89 89.90 10 21.28
ADT 0 0.00 4 5.19 0 0.00 2 4.26
Table 4: (a) Treatment Choice Stratiﬁed by Gleason Score and Age (<70yrs). (b) Treatment Choice Stratiﬁed by Gleason Score and Age
(>70yrs).
(a)
Pre-investment Post-investment
<70yrs % <70yrs %
Gls 6
A S 33 . 3 358 . 4 7
XRT 4 4.44 2 3.39
RP 83 92.22 51 86.44
Gls 7
A S 0000
XRT 2 8 2 5.71
RP 23 92 33 94.29
Gls 8+
A S 0000
X R T0000
RP 6 100 5 100
(b)
Pre-Investment Post-Investment
>70y % >70y %
Gls 6
AS 6 15.79 8 34.78
XRT 16 42.11 10 43.48
RP 12 31.58 5 21.74
Gls 7
AS 0 0 1 5.26
XRT 12 41.38 13 68.42
RP 16 55.17 3 15.79
Gls 8+
A S 0000
XRT 7 70 3 60
R P 22 024 0
of grade 2 rectal morbidity and no grade 4 or greater
rectal complications in patients with clinically localized PCa.
Furthermore, IMRT has been shown to reduce the acute and
late GI toxicity of patients treated with high-dose radiation
therapy and adjuvant androgen deprivation as compared
to 3 D conformal radiotherapy [8]. This reduction in GU
and GI morbidity has made IMRT extremely popular in the
delivery of high-dose external beam radiation for patients
with clinically localized PCa in the United States.
Since 2004 several large urology groups in partnership
with radiation and medical oncologists have established
centers of integrated prostate cancer care. These centersISRN Urology 5
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Figure 4: (a) Treatment choice stratiﬁed by gleason score and age (<70yrs). (b) Treatment choice stratiﬁed by gleason score and age
(>70yrs).
provide for a collaborative approach to the treatment of PCa.
The integrated care model is patient-centered and disease
speciﬁc, where the equipment and the staﬀ are dedicated to
the treatment of PCa and no other disease entity. Although
yettobevalidated,thismodelmaypotentiallyresultinbetter
recognitionandmanagementoftreatment-relatedcomplica-
tions, improved access to care, and increased experience with
each treatment modality and thus better clinical outcomes.
Recently, these centers have become the targets of intense
criticism [3, 4]. The detractor’s claim that integrated PCa
carecentersleadtoself-referralbyﬁnanciallymotivatedurol-
ogists and radiation oncologists and resultin over-utilization
of IMRT contributing to the increased cost of health care.
They further claim that these centers have a negative impact
on residency training in radiation oncology by shifting
patients away from the academic radiation oncology training6 ISRN Urology
programs. Unfortunately, these claims are not substantiated
by data, but rather rely on indirect analysis of Medicare
claims and a 12% negative impact report from a single 3-
point questionnaire survey of 81 radiation oncology training
programs [3, 4].
To our knowledge, this is a ﬁrst study conducted to
directlyevaluatewhetherﬁnancialinterestinIMRTaspartof
the integrated prostate cancer care model changed treatment
recommendationsfornewlydiagnosedpatientswithprostate
cancer. We compared the distribution of treatments choices
of all consecutive patients diagnosed with prostate cancer on
a biopsy in our practice during a 12-month period prior to
acquiring ﬁnancial interest in IMRT to a 12-month period
following that acquisition. Our analysis revealed that overall
there was a small, but statistically insigniﬁcant decrease in
the use of radiation therapy and radical prostatectomy and
a small increase in the use of active surveillance following
investment in IMRT. The increased use of active surveillance
is likely due to the emergence of data from several large
trials supporting the safety and eﬃcacy of this approach in
appropriately selected patients [11–13].
Once the data were stratiﬁed by Gleason score and
patient age, a statistically signiﬁcant increase in the use of
radiation was found in men over 70 with Gleason 7 disease
(41.3% versus 68.3%). However, because of the overall low
number of patients in this subgroup, this increase was due to
a single patient diﬀerence between the groups (12 versus 13).
These ﬁndings are not surprising as we believe that
severalimportantattributesofourintegratedprostatecancer
program provide for many patient beneﬁts without the
recently theorized, yet unsubstantiated risks of overutiliza-
tion of IMRT. As previously described, our center was estab-
lished in collaboration with an academic radiation oncology
department from an NCI designated cancer center with a
nationwide reputation for clinical and academic excellence.
The radiation oncologists that treat our patients are not
employed by the integrated prostate cancer center, but rather
serve as full-time academic faculty and have no ﬁnancial
interest in IMRT. Furthermore, the ﬁnal determination on
whether a patient is an appropriate candidate for primary or
adjuvant radiation therapy is made entirely by the treating
radiation oncologist. Radiation oncology residents have the
opportunity to participate in all aspects of planning and
delivery of IMRT, thus deriving an educational beneﬁt from
this partnership. All patients are considered and frequently
enrolled into the RTOG-sponsored randomized trials. The
center employs a nurse-practitioner charged exclusively with
coordination and support of the clinical research program.
Additionally, we are privileged to have CME accreditation by
our state medical society and conduct regularly scheduled
multidisciplinary morbidity and mortality conferences and
discussions of challenging cases. Finally, we maintain a very
high volume surgical program that ranks second in the
numberofradicalprostatectomiesperformedannuallyinthe
greater Philadelphia, PA, USA.
Our study has several limitations that must be acknowl-
edged. First, this study is underpowered due to a fairly low
number of patients and therefore the results of our statistical
analysis must withstand the test of a larger trial for our
conclusions to be validated. Second, even though we at-
tempted to minimize limitations of the retrospective study
design by including all consecutive patients diagnosed with
prostate cancer within the 24-month period, the selection
bias inherent in retrospective study design was not com-
pletely eliminated. Third, we did not include patients under-
going adjuvant or salvage radiation therapy in the trial and
therefore did not ascertain the eﬀect of ﬁnancial interest in
IMRT on utilization of radiation in these patients. Finally,
our ﬁndings may not be applicable to other integrated
prostatecancercentersbecauseoftheuniquestructureofour
speciﬁc program.
5. Conclusion
Financial interest in IMRT does not result in an increased
utilization of radiation therapy in the treatment of newly
diagnosed patients with clinically localized prostate cancer in
ourintegratedprostatecancercenter.Alargeprospectivetrial
is warranted to validate these initial ﬁndings.
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